Type I Interferon Inhibition of MicroRNA-146a Maturation Through Up-Regulation of Monocyte Chemotactic Protein-Induced Protein 1 in Systemic Lupus Erythematosus

Arthritis Rheumatol. 2015 Dec;67(12):3209-18. doi: 10.1002/art.39398.

Abstract

Objective: Systemic lupus erythematosus (SLE) is characterized by the uncontrolled production of inflammatory cytokines, among which type I interferon (IFN) is recognized as a crucial pathogenic factor. The expression of microRNA-146a (miR-146a) is reduced in the white blood cells of SLE patients and accounts for their overactivated inflammatory responses. However, the mechanism of the reduction of miR-146a is still not fully understood. This study was undertaken to test whether the key pathogenic cytokine, type I IFN, is responsible for the dysregulation of miR-146a in SLE.

Methods: Gene and protein expression was measured in all cells by reverse transcription-quantitative polymerase chain reaction, Northern blotting, or Western blotting. In THP-1 cells, expression of monocyte chemotactic protein-induced protein 1 (MCPIP-1) was knocked down with a lentivirus encoding a short hairpin RNA targeting MCPIP1. The cells were pretreated with type I IFN and assessed for gene expression levels of miR-146a. White blood cells from patients with SLE were analyzed for the expression of the IFN-inducible genes MCPIP1 and miR-146a, and the gene expression data were compared for correlation.

Results: Pretreatment of THP-1 cells with type I IFN attenuated the induction of miR-146a posttranscriptionally, by down-regulating the expression of pre-miR-146a but not pri-miR-146a or its original unspliced transcript. Expression of MCPIP-1, which was enhanced by type I IFN, was found to be responsible for the inhibition of miR-146a. In white blood cells from patients with SLE, MCPIP1 expression was elevated, and its expression correlated positively with the IFN score and negatively with the miR-146a transcript level.

Conclusion: Type I IFN inhibits the maturation of miR-146a through the up-regulation of MCPIP-1, and thus contributes to the uncontrolled inflammation and excessive inflammatory gene expression in SLE.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2',5'-Oligoadenylate Synthetase / genetics
  • 2',5'-Oligoadenylate Synthetase / immunology
  • Antigens, Surface / genetics
  • Antigens, Surface / immunology
  • Cell Line
  • GPI-Linked Proteins / genetics
  • GPI-Linked Proteins / immunology
  • Gene Expression
  • Gene Knockdown Techniques
  • Humans
  • Interferon Type I / genetics
  • Interferon Type I / immunology
  • Interferon Type I / pharmacology*
  • Leukocytes / immunology
  • Lipopolysaccharides / pharmacology
  • Lupus Erythematosus, Systemic / genetics*
  • Lupus Erythematosus, Systemic / immunology
  • MicroRNAs / drug effects*
  • MicroRNAs / genetics
  • MicroRNAs / immunology
  • Monocytes / drug effects*
  • Monocytes / immunology
  • Myxovirus Resistance Proteins / genetics
  • Myxovirus Resistance Proteins / immunology
  • RNA, Messenger / drug effects*
  • RNA, Messenger / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Ribonucleases / drug effects*
  • Ribonucleases / genetics
  • Ribonucleases / immunology
  • Transcription Factors / drug effects*
  • Transcription Factors / genetics
  • Transcription Factors / immunology
  • Up-Regulation / drug effects

Substances

  • Antigens, Surface
  • GPI-Linked Proteins
  • Interferon Type I
  • LY6E protein, human
  • Lipopolysaccharides
  • MIRN146 microRNA, human
  • MX1 protein, human
  • MicroRNAs
  • Myxovirus Resistance Proteins
  • RNA, Messenger
  • Transcription Factors
  • OAS1 protein, human
  • 2',5'-Oligoadenylate Synthetase
  • Ribonucleases
  • ZC3H12A protein, human